CT-P13: design, development, and place in therapy [PDF]
Tommaso Gabbani,1 Simona Deiana,2 Vito Annese3 1Gastroenterology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, 2Division of Gastroenterology, AOU Careggi University Hospital, Florence, Italy; 3Gastroenterology Department, Valiant ...
Gabbani T, Deiana S, Annese V
doaj +7 more sources
Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease [PDF]
Background and aimsFavourable clinical data were published on the efficacy of CT-P13, the first biosimilar of infliximab (IFX), in pediatric inflammatory bowel disease (IBD); however, few studies have compared the effect on endoscopic healing (EH) and ...
Eun Sil Kim +31 more
doaj +6 more sources
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients [PDF]
Many reference biological therapies have now reached or are near to patent expiry, and therefore a number of biosimilars have been or will be developed.
Jørgen Jahnsen
doaj +4 more sources
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Joana Afonso +5 more
doaj +6 more sources
A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®). [PDF]
To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions.This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel ...
Kim S, Kim S, Lee H.
europepmc +10 more sources
Comparative effectiveness of the biosimilar CT-P13
The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries.
Dae Hyun Yoo
core +4 more sources
A Review on Biosimilar Infliximab, CT-P13, in the Treatment of Inflammatory Bowel Disease [PDF]
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however ...
Farkas Klaudia, Molnár Tamás
openaire +5 more sources
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study [PDF]
Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation.
Jose M. Huguet +11 more
doaj +2 more sources
Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series [PDF]
The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased ...
Sooraj Vijayan +2 more
doaj +2 more sources
Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU
CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after ...
Matt Shirley (7340599)
openaire +3 more sources

